In a bid to reduce the mortality rate, Switzerland based Ferring Pharmaceutical has designed a heat stable carbetocin which is as effective as oxytocin, the current standard of care in preventing excessive bleeding during child birth.
The effective propagation of heat stable carbetocin will ensure the prevention of Postpartum hemorrhage (PPH) related deaths in India due to its easy storage at high temperatures which is usually difficult with normal oxytocin.
The results of the CHAMPION clinical trial, conducted by WHO as part of a collabortaion with Ferring and MSD for Mothers, were published in the New England Journal of Medicine (NEJM)
“This is an important step forwards in PPH prevention and these results pave the way for heat-stable carbetocin to potentially save the lives of thousands of women, especially in areas where cold-chain transport and storage is not feasible,” said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals.
“We will now work with the WHO and MSD for Mothers to make heat-stable carbetocin available in countries where it is needed most, protecting women and families around the world.”
Studies in low- and lower-middle income countries have revealed degradation and loss of efficacy in oxytocin .
Heat-stable carbetocin has the potential to save thousands of women’s lives in low- and lower-middle income countries, where 99% of PPH-related deaths occur and where the refrigeration of medicines can be difficult to achieve and maintain.
It is estimated that, India contributes to about a quarter of all global maternal deaths due to postpartum haemorrhage (PPH), estimating to 45,000 death of mothers during childbirth every year.